ArticleNature2021
Structure-based classification predicts drug response in EGFR-mutant NSCLC.
Registry-linked trialOpen access · hybridAbstract read
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06062823 (An Open-label Phase II Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations Categorized According to Structural Based Classification), which is not on this map. Cited by 291 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
291citing papers in PubMed, 1 pooled it
41.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-label Phase II Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations Categorized According to Structural Based Classification
Who cites it
291 citing papers in PubMed, 1 synthesis or guideline pooled it, 427 citations in OpenAlex.
- [Clinical Practice Guidelines for the Management of Brain Metastases from Non-small Cell Lung Cancer with Actionable Gene Alterations in China (2025 Edition)].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Guideline
- An Observational Study of Afatinib 30 mg Daily in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Common EGFR Mutations Treated With Afatinib.Thoracic cancer · 2026Trial
- Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity.Nature communications · 2025Trial
- Phase II study of afatinib for advanced non-small cell lung cancer with uncommon epidermal growth factor receptor mutations, including compound mutations detected by next-generation sequencing.International journal of clinical oncology · 2025Trial
- A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-NaïveJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Variant-Specific Landscape of Mutual Exclusivity Among BRAF, EGFR, and KRAS Oncogenes Reveals Overlap With Functionally Antagonistic Mutant Pairs.International journal of cancer · 2026Article
- Integrating clinical outcomes with molecular simulations to guide the selection of non-classical EGFR-TKIs: A comprehensive analysis and development of treatment strategies.Experimental and therapeutic medicine · 2026Article
- Empowering Inference of Epistasis on the Basis of Mutual Exclusivity, Co-Occurrence, Functional Antagonism and Synergy in ERK-Pathway Oncogenes.International journal of cancer · 2026Article
- Retrospective real-world associations betweenTranslational lung cancer research · 2026Article
- Predicting Oncogenic Mutants of Epidermal Growth Factor Receptor in Lung Cancer by Molecular Dynamics Simulation with Machine Learning.ACS omega · 2026Article
- Landscape of Chinese Lung Cancer Patients With Compound Mutations and Acquired Resistance Alterations: A Retrospective Study.International journal of cancer · 2026Article
- Article
- Multiparatopic antibodies overcome tyrosine kinase inhibitor resistance by inducing lysosomal degradation of EGFR mutants.Oncogene · 2026Article
- Human biomarker navigator.iMeta · 2026Review
- Towards better outcomes for epidermal growth factor receptor L858R+ lung cancer patients: mutant-selective allosteric inhibitors and the potential for double-drugging.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2026Review
- Epidermal Growth Factor Receptor as a Model Drug Target for Scrutinizing the Status Quo in Drug Discovery and Chemical Biology.ACS bio & med chem Au · 2026Review
- Novel Co-Occurrence of GermlineInternational journal of molecular sciences · 2026Article
- Molecular tumor board-guided osimertinib therapy in EGFR L858R/Q701L-mutant lung adenocarcinoma supported by functional validation.The oncologist · 2026Article
- Cancer drug response and resistance: molecular mechanisms and combating strategies.Signal transduction and targeted therapy · 2026Review
- Should we optimise or revise the management of initially unresectable stage III non-small cell lung cancer: rethinking consolidation therapy.Journal of the National Cancer Center · 2026Article
231 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
33 authors at 4 institutions in 2 countries.
Jacqulyne P RobichauxDepartment of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Xiuning LeDepartment of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
R S K VijayanInstitute for Applied Cancer Science, MD Anderson Cancer Center, Houston, TX, USA.
J Kevin HicksDepartment of Individualized Cancer Management, Moffitt Cancer Center, Tampa, FL, USA.
Simon HeekeDepartment of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-5916-534X
Yasir Y ElaminDepartment of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-5312-909X
Heather Y LinDepartment of Biostatistics, MD Anderson Cancer Center, Houston, TX, USA.
Hibiki UdagawaDepartment of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Ferdinandos SkoulidisDepartment of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Hai TranDepartment of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Susan VargheseDepartment of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Junqin HeDepartment of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Fahao ZhangDepartment of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Monique B NilssonDepartment of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Lemei HuDepartment of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Alissa PoteeteDepartment of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Waree RinsurongkawongQuantitative Research Computing, MD Anderson Cancer Center, Houston, TX, USA.
Xiaoshan ZhangDepartment of Thoracic and Cardiovascular Surgery, MD Anderson Cancer Center, Houston, TX, USA.
Chenghui RenDepartment of Thoracic and Cardiovascular Surgery, MD Anderson Cancer Center, Houston, TX, USA.
Xiaoke LiuDepartment of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Lingzhi HongDepartment of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Jianjun ZhangDepartment of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-7872-3477
Lixia DiaoDepartment of Bioinformatics and Computational Biology, MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-6995-4492
Russell MadisonFoundation Medicine, Cambridge, MA, USA.
Alexa B SchrockFoundation Medicine, Cambridge, MA, USA.
Jennifer SaamGuardant Health, Redwood City, CA, USA.
Victoria RaymondGuardant Health, Redwood City, CA, USA.
Bingliang FangDepartment of Thoracic and Cardiovascular Surgery, MD Anderson Cancer Center, Houston, TX, USA.
Jing WangDepartment of Bioinformatics and Computational Biology, MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-5398-0802
Min Jin HaDepartment of Biostatistics, MD Anderson Cancer Center, Houston, TX, USA.
Jason B CrossInstitute for Applied Cancer Science, MD Anderson Cancer Center, Houston, TX, USA.
Jhanelle E GrayDepartment of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL, USA.
John V HeymachDepartment of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA. JHeymach@mdanderson.org.ORCID http://orcid.org/0000-0001-9068-8942
The University of Texas MD Anderson Cancer Center · USFoundation Medicine (United States)Guardant (United States) · USMoffitt Cancer Center · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MUNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V., MINNA, JOHN D. · 1996 to 2024
$57.4MUniversity of Texas PDX Development and Trial CenterU54CA224065 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAMODARAN, SENTHILKUMAR, MERIC-BERNSTAM, FUNDA · 2017 to 2022
$7.7MMolecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitorsR01CA247975 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HEYMACH, JOHN V., JONES, PHILIP · 2020 to 2024
$2.8MTherapeutic strategies against EGFR exon 20 mutant lung cancerR01CA234183 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HEYMACH, JOHN V., WONG, KWOK KIN · 2020 to 2024
$2.8MOvercoming Resistance to Anti-EGFR Therapy by Drug RepurposingR01CA190628 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FANG, BINGLIANG, HEYMACH, JOHN V. · 2015 to 2019
$2.6MTargeting EGFR mutant tyrosine kinase inhibitors (TKIs) resistant and drug-tolerant persister cells in non-small cell lung cancer (NSCLC)R50CA265307 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI NILSSON, MONIQUE B · 2021 to 2025
$585kNCI NIH HHS P30 CA016672NCI NIH HHS P50 CA070907NCI NIH HHS R01 CA190628NCI NIH HHS R01 CA234183NCI NIH HHS R01 CA247975NCI NIH HHS R50 CA265307NCI NIH HHS U54 CA224065
Abstract
Epidermal growth factor receptor (EGFR) mutations typically occur in exons 18-21 and are established driver mutations in non-small cell lung cancer (NSCLC)
Indexed as
AfatinibAnimalsAntineoplastic AgentsCarcinoma, Non-Small-Cell LungCell Line, TumorDrug RepositioningDrug Resistance, NeoplasmErbB ReceptorsExonsFemaleHumansLung NeoplasmsMiceMolecular Docking SimulationMutationStructure-Activity RelationshipAfatinibAntineoplastic AgentsEGFR protein, humanErbB Receptors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT06062823ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.